Biomarker comparison

ApoB vs LDL cholesterol: particle count versus cargo, and which to treat to

Short answer

LDL cholesterol measures how much cholesterol is riding inside LDL particles; apolipoprotein B counts the particles themselves — one ApoB per LDL, VLDL, IDL and Lp(a) particle — and it is the particle, not the cargo, that lodges in artery walls. The two agree in most people, which is why LDL-C has served for fifty years. They diverge when particles are small and cholesterol-poor — high triglycerides, insulin resistance, diabetes, obesity, metabolic syndrome — and there ApoB shows risk that LDL-C hides. In head-to-head analyses ApoB predicts events better and explains the risk that LDL-C and triglycerides only approximate. Guidelines now use both: the 2018 AHA/ACC treats ApoB of 130 mg/dL or more as a risk enhancer, and the 2019 ESC/EAS sets ApoB targets alongside LDL-C.

Medically reviewed by Youmna DiStefano, MD · Last reviewed November 2026

Apolipoprotein B vs LDL Cholesterol side by side

	Apolipoprotein B	LDL Cholesterol
What it measures	The number of atherogenic lipoprotein particles — one ApoB molecule per LDL, VLDL, IDL and Lp(a) particle	The mass of cholesterol carried inside LDL particles, usually calculated from the standard lipid panel
Normal range (adults)	age 18+: 0 – 90 mg/dL	age 18+: 0 – 100 mg/dL
Fasting	Not required	Not required for most decisions; needed when triglycerides are above 400 mg/dL because the calculation fails
Targets	Under 90 mg/dL for most adults; under 80 at high risk and under 65 at very high risk (ESC/EAS 2019); 130 or more is a risk enhancer (AHA/ACC 2018)	Under 100 mg/dL for most adults; under 70 with cardiovascular disease or diabetes (ESC/EAS: under 55 at very high risk); 190 or more is treated regardless
When they disagree	Higher than LDL-C suggests — small, dense, numerous particles: high triglycerides, insulin resistance, diabetes, obesity, very low LDL-C on treatment	Looks fine while ApoB is high in about one in five people; overstates risk in the few with large, cholesterol-rich particles
What lowers it	The same drugs and diet as LDL-C — statins 30–50%, ezetimibe, PCSK9 inhibitors; weight loss and triglyceride lowering reduce it more than they reduce LDL-C	Diet 10–20%, statins 30–50% or more, ezetimibe, PCSK9 inhibitors, bempedoic acid
Guideline status	Risk enhancer in the U.S. guideline; a formal target in the European one and the primary target in Canada's	The primary target in every guideline and the number every trial was run on

Reference ranges are the reviewed catalog ranges for adults; your laboratory's printed range may differ slightly.

Particles versus cargo

Atherosclerosis starts when an ApoB-carrying particle crosses the artery wall and is trapped there, and the chance of that happening depends on how many particles are circulating, not on how much cholesterol each one holds. LDL cholesterol was adopted because it was measurable and because, in most people, particle number and cholesterol mass rise and fall together. ApoB measures the thing that matters directly: one molecule per particle, so the concentration is the count.

The difference matters when particles are not average. A person with high triglycerides and insulin resistance makes many small, cholesterol-depleted LDL particles; their LDL-C can read 95 mg/dL while their ApoB reads 110 — the same number of particles as someone with an LDL-C of 140. The reverse, large cholesterol-rich particles with a high LDL-C and an unremarkable ApoB, is less common and carries less risk than the LDL-C suggests.

When ApoB tells a different story

ApoB is worth measuring, or adds to LDL-C, in a specific set of people:

Triglycerides above about 150 mg/dL, especially above 200 — the calculated LDL-C becomes less reliable and particles become smaller.
Type 2 diabetes, prediabetes, metabolic syndrome, abdominal obesity or fatty liver — the discordant pattern is common, and the UK Biobank and other cohorts show ApoB captures their risk where LDL-C understates it.
On treatment with an LDL-C already low — a residual high ApoB identifies people who are still carrying too many particles and may need more intensive therapy.
Borderline statin decisions — an ApoB of 130 mg/dL or more is one of the risk-enhancing factors the AHA/ACC guideline uses to favor starting.
Very high or very low HDL, or a family history of early heart disease that the standard panel does not explain.

What the guidelines say

The 2018 AHA/ACC cholesterol guideline keeps LDL-C as the treatment target and uses ApoB (130 mg/dL or more, roughly an LDL-C of 160) as a risk-enhancing factor in intermediate-risk adults. The 2019 ESC/EAS guideline recommends ApoB for risk assessment in people with high triglycerides, diabetes, obesity, metabolic syndrome or very low LDL-C, and sets ApoB targets of under 65, 80 and 100 mg/dL for very-high, high and moderate risk. The Canadian Cardiovascular Society made ApoB (or non-HDL cholesterol) the preferred target in 2021. Across all three, when LDL-C and ApoB disagree, ApoB is the number to believe.

How to read the two together

Four patterns cover most results:

Both high — the usual pattern; treat to the LDL-C target and confirm ApoB falls with it.
LDL-C normal, ApoB high — discordance: too many small particles, usually with high triglycerides or insulin resistance; the risk is real, and weight, triglycerides and often a statin are addressed. High ApoB has its own page.
LDL-C high, ApoB normal — fewer, larger particles; risk is lower than the LDL-C implies, though an LDL-C of 190 or more is still treated.
Both low — the target state on or off treatment; residual risk, if any, comes from lipoprotein(a), blood pressure, glucose and smoking rather than from the LDL.

How do you test Apolipoprotein B and LDL Cholesterol?

Prices are cash-pay; every order adds one $6 lab processing fee. Physician authorization is included; no insurance or referral needed.

Test or panel	Type	Price	Fasting	Results
Heart Health Panel	Panel · 5 tests	$99.99	Yes	3–5 business days
Longevity & Anti-Aging Panel	Panel · 13 tests	$259.99	Yes	3–7 business days
General Wellness Advanced Panel	Panel · 14 tests	$209.99	Yes	2–4 business days
Advanced Lipid Panel	Test · 8 biomarkers	$90.99	Yes	3–5 business days

Common questions

Should I test ApoB instead of LDL?

In addition to, not instead of — at least once. A standard lipid panel is still the screening test and the one guidelines dose statins against, and in most people ApoB and LDL-C agree. ApoB earns its place if you have high triglycerides, diabetes or prediabetes, abdominal weight, metabolic syndrome, a strong family history, or an LDL-C that is already low on treatment; in those groups it can show risk the panel misses. It needs no fasting and is inexpensive.

What is a good ApoB level?

Under 90 mg/dL for most adults; under 80 if you are at high cardiovascular risk and under 65 with established cardiovascular disease or diabetes with organ damage, per the European guideline. An ApoB of 130 mg/dL or more is a risk-enhancing factor in the U.S. guideline. As with LDL-C, lower is better across the whole range, and the target depends on your overall risk rather than on a single universal cutoff.

Can ApoB be high with a normal LDL?

Yes — in roughly one in five adults, and more often with high triglycerides, insulin resistance, type 2 diabetes or obesity. The LDL particles are small and carry little cholesterol each, so LDL-C looks acceptable while the particle count is high. That discordant pattern carries the risk of the ApoB, not the LDL-C, and is one of the main reasons the test exists.

Does a statin lower ApoB?

Yes — statins lower ApoB by roughly 30–50% at the same time as LDL-C, as do ezetimibe (about 15%) and PCSK9 inhibitors (50–60%). ApoB tends to fall slightly less than LDL-C in percentage terms, which is why a residual high ApoB on treatment is checked in people with high triglycerides or diabetes. Weight loss and triglyceride lowering shrink the particle count more than they change LDL-C.

Sources

Educational content, not a diagnosis. Lab results are one input; a clinician interprets them with your history and exam.